Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma



      Small bowel adenocarcinoma (SBA) is a rare malignancy affecting approximately 3000 patients per year in the United States, and there is limited evidence prognosticating patients with resected SBA. We aimed to evaluate prognostic factors and the role of adjuvant therapy in patients with resected SBA.

      Patients and Methods

      Two hundred forty-one patients who had resected stage I-III SBA were retrospectively identified at a single tertiary referral institution. Overall survival (OS) analysis was performed by the Kaplan-Meier method, and Wilcoxon tests were used for statistical comparisons. Cox proportional hazards were performed to identify significant variables by univariate and multivariate analysis.


      Median OS for the entire group was 54.5 months (95% confidence interval [CI], 37.2-81.2 months), with 5- and 10-year OS of 48% and 35%. Median follow-up was 113.7 months (95% CI, 97.9-126.6 months). For patients with stage III disease who received adjuvant therapy, the median OS was 33.8 months (95% CI, 27.8-78.8) compared to 24.7 months (95% CI, 11.5-37.8) for patients with no adjuvant therapy (P < .01). Male sex, advanced T stage, advanced N stage, increased positive lymph node ratio, lymphocyte-to-monocyte ratio < 1.56, presence of residual disease, and earlier date of diagnosis predicted worse survival on univariate analysis. Age > 60 years, lymphocyte-to-monocyte ratio < 1.56, and advanced T stage were identified as independent negative predictors of OS for all patients by multivariate analysis.


      Advanced age, advanced T stage, and lymphocyte-to-monocyte ratio < 1.56 independently predicted survival in resected SBA. Adjuvant therapy is associated with improved survival in patients with resected stage III SBA.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30
        • Hatzaras I.
        • Palesty J.A.
        • Abir F.
        • et al.
        Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the connecticut tumor registry.
        Arch Surg. 2007; 142: 229-235
        • Bilimoria K.Y.
        • Bentrem D.J.
        • Wayne J.D.
        • et al.
        Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.
        Ann Surg. 2009; 249: 63-71
        • Howe J.R.
        • Karnell L.H.
        • Menck H.R.
        • et al.
        American College of Surgeons Commission on Cancer; American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995.
        Cancer. 1999; 86: 2693-2706
        • Ecker B.L.
        • McMillan M.T.
        • Datta J.
        • et al.
        Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: a propensity score–matched analysis.
        Cancer. 2016; 122: 693-701
        • Neoptolemos J.P.
        • Moore M.J.
        • Cox T.F.
        • et al.
        Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
        JAMA. 2012; 308: 147-156
        • Overman M.J.
        • Kopetz S.
        • Lin E.
        • et al.
        Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine.
        Acta Oncol. 2010; 49: 474-479
        • Fishman P.N.
        • Pond G.R.
        • Moore M.J.
        • et al.
        Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.
        Am J Clin Oncol. 2006; 29: 225-231
        • McWilliams R.R.
        • Foster N.R.
        • Mahoney M.R.
        • et al.
        North Central Cancer Treatment Group N0543 (Alliance): a phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
        Cancer. 2017; 123: 3494-3501
        • Gibson M.K.
        • Holcroft C.A.
        • Kvols L.K.
        • et al.
        Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
        Oncologist. 2005; 10: 132-137
        • Raghav K.
        • Overman M.J.
        Small bowel adenocarcinomas—existing evidence and evolving paradigms.
        Nat Rev Clin Oncol. 2013; 10: 534-544
        • Locher C.
        • Batumona B.
        • Afchain P.
        • et al.
        Small bowel adenocarcinoma: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).
        Dig Liver Dis. 2018; 50: 15-19
        • Abrahams N.A.
        • Halverson A.
        • Fazio V.W.
        • et al.
        Adenocarcinoma of the small bowel: a study of 37 cases with emphasis on histologic prognostic factors.
        Dis Colon Rectum. 2002; 45: 1496-1502
        • Agrawal S.
        • McCarron E.C.
        • Gibbs J.F.
        • et al.
        Surgical management and outcome in primary adenocarcinoma of the small bowel.
        Ann Surg Oncol. 2007; 14: 2263-2269
        • Koo D.H.
        • Yun S.C.
        • Hong Y.S.
        • et al.
        Adjuvant chemotherapy for small bowel adenocarcinoma after curative surgery.
        Oncology. 2011; 80: 208-213
        • Failing J.J.
        • Yan Y.
        • Porrata L.F.
        • et al.
        Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients.
        Melanoma Res. 2017; 27: 596-600
        • Porrata L.F.
        • Ristow K.
        • Colgan J.P.
        • et al.
        Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma.
        Haematologica. 2012; 97: 262-269
        • Khan K.
        • Peckitt C.
        • Sclafani F.
        • et al.
        Prognostic factors and treatment outcomes in patients with small bowel adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience.
        BMC Cancer. 2015; 15: 15
        • Halfdanarson T.R.
        • McWilliams R.R.
        • Donohue J.H.
        • et al.
        A single-institution experience with 491 cases of small bowel adenocarcinoma.
        Am J Surg. 2010; 199: 797-803
      1. Edge S.B. Byrd D.R. Compton C.C. Fritz A.G. Greene F.L. Trotti A. AJCC Cancer Staging Manual. 7th ed. Springer, New York, NY2010
        • Williams B.A.
        • Mandrekar H.N.
        • Cha S.S.
        • Furth A.F.
        Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes. Technical Report Series #79. Rochester, MN: Mayo Foundation; 2006..
        (Available at:)
        • Locher C.
        • Malka D.
        • Boige V.
        • et al.
        Combination chemotherapy in advanced small bowel adenocarcinoma.
        Oncology. 2005; 69: 290-294
        • Andre T.
        • Boni C.
        • Mounedji-Boudiaf L.
        • et al.
        Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
        N Engl J Med. 2004; 350: 2343-2351
        • Andre T.
        • Boni C.
        • Navarro M.
        • et al.
        Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
        J Clin Oncol. 2009; 27: 3109-3116
        • Sohn T.A.
        • Lillemoe K.D.
        • Cameron J.L.
        • et al.
        Adenocarcinoma of the duodenum: factors influencing long-term survival.
        J Gastrointest Surg. 1998; 2: 79-87
        • Nishijima T.F.
        • Muss H.B.
        • Shachar S.S.
        • et al.
        Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis.
        Cancer Treat Rev. 2015; 41: 971-978
        • Stotz M.
        • Pichler M.
        • Absenger G.
        • et al.
        The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer.
        Br J Cancer. 2014; 110: 435-440
        • Thota R.
        • Gonzalez R.S.
        • Berlin J.
        • et al.
        Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma?.
        Am J Clin Pathol. 2017; 148: 208-214
        • Mlecnik B.
        • Tosolini M.
        • Kirilovsky A.
        • et al.
        Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.
        J Clin Oncol. 2011; 29: 610-618
        • Yan Y.
        • Kumar A.B.
        • Finnes H.
        • et al.
        Combining immune checkpoint inhibitors with conventional cancer therapy.
        Front Immunol. 2018; 9: 1739